Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) Director Beth C. Seidenberg sold 1,177 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the sale, the director now directly owns 160,376 shares in the company, valued at approximately $6,737,395.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Vera Therapeutics Stock Up 1.9 %
VERA stock opened at $42.78 on Friday. The stock has a market capitalization of $2.34 billion, a PE ratio of -20.87 and a beta of 0.99. Vera Therapeutics, Inc. has a 52 week low of $9.24 and a 52 week high of $50.78. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $37.47 and a 200 day moving average of $39.09.
Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.06). Sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current year.
Analyst Upgrades and Downgrades
Read Our Latest Stock Report on Vera Therapeutics
Institutional Trading of Vera Therapeutics
Large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. boosted its holdings in shares of Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after acquiring an additional 688 shares during the last quarter. Arizona State Retirement System boosted its holdings in Vera Therapeutics by 14.4% in the second quarter. Arizona State Retirement System now owns 9,907 shares of the company’s stock valued at $358,000 after purchasing an additional 1,250 shares during the last quarter. Ensign Peak Advisors Inc grew its position in Vera Therapeutics by 13.5% during the 2nd quarter. Ensign Peak Advisors Inc now owns 11,750 shares of the company’s stock worth $425,000 after purchasing an additional 1,400 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Vera Therapeutics by 30.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock valued at $272,000 after buying an additional 1,737 shares during the last quarter. Finally, American International Group Inc. lifted its holdings in shares of Vera Therapeutics by 17.6% in the 1st quarter. American International Group Inc. now owns 19,764 shares of the company’s stock valued at $852,000 after buying an additional 2,957 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.
About Vera Therapeutics
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Featured Articles
- Five stocks we like better than Vera Therapeutics
- What Are Dividend Champions? How to Invest in the Champions
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Industrial Products Stocks Investing
- MarketBeat Week in Review – 9/16 – 9/20
- The Significance of Brokerage Rankings in Stock Selection
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.